These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 19744723)

  • 1. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
    Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
    Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
    Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
    Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
    Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
    Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
    Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
    Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
    Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
    Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of retinal sensitivity to ranibizumab treatment of macular edema after acute branch retinal vein occlusion.
    Mylonas G; Sacu S; Dunavoelgyi R; Matt G; Blum R; Buehl W; Pruente C; Schmidt-Erfurth U;
    Retina; 2013 Jun; 33(6):1220-6. PubMed ID: 23584689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
    Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
    Retina; 2007; 27(4):419-25. PubMed ID: 17420692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.